+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Scleroderma Diagnostics & Therapeutics Market - Global Forecast to 2030- Product Image
Scleroderma Diagnostics & Therapeutics Market - Global Forecast to 2030- Product Image
Sale

Scleroderma Diagnostics & Therapeutics Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 196 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6012574
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Scleroderma Diagnostics & Therapeutics Market grew from USD 2.19 billion in 2024 to USD 2.34 billion in 2025. It is expected to continue growing at a CAGR of 6.47%, reaching USD 3.20 billion by 2030.

Scleroderma, a complex autoimmune disorder characterized by skin fibrosis and vascular abnormalities, presents a formidable challenge to clinicians and patients alike. This executive summary synthesizes recent advances in diagnostic methodologies and therapeutic interventions, highlighting key breakthroughs that promise to reshape patient outcomes. By examining emerging biomarkers, novel imaging modalities, and targeted pharmacotherapies, stakeholders can better navigate an evolving landscape marked by technological innovation and regulatory shifts. As the burden of systemic sclerosis intensifies-spanning from limited cutaneous involvement to life-threatening organ complications-early detection and tailored treatment strategies are paramount. This paper begins with an overview of foundational trends, paving the way for deeper insights into transformative shifts, tariff implications, segmentation analysis, regional dynamics, competitive positioning, actionable recommendations, and a strategic call to action. Through a cohesive narrative, decision-makers will gain clarity on high-impact opportunities and potential obstacles, laying the groundwork for more informed investments and collaborations across the fields of immunology, rheumatology, and beyond.

Transformative Shifts in the Landscape

The past decade has seen transformative shifts that are redefining the approach to scleroderma care. At the forefront, high-resolution imaging paired with molecular diagnostics is enabling clinicians to identify subclinical fibrosis earlier than ever before, shifting the paradigm from symptom-driven intervention to preemptive management. Concurrently, the integration of artificial intelligence into histopathological examination accelerates diagnostic accuracy and consistency, reducing reliance on subjective interpretation. On the therapeutic front, the rise of antifibrotic agents and immunomodulatory biologics is expanding the treatment armamentarium beyond traditional calcium channel blockers and vasodilators, fostering more personalized regimens. Moreover, an increased emphasis on non-pharmacological therapies such as occupational and physical therapy underscores a holistic model of care that addresses functional outcomes alongside clinical metrics. These converging trends signal a departure from one-size-fits-all protocols toward data-driven, patient-centric pathways, setting the stage for sustained improvements in quality of life and long-term prognosis.

Cumulative Impact of United States Tariffs 2025

As the United States moves into 2025, revised tariff policies are poised to exert cumulative effects on the supply chain for diagnostics and therapeutics. Tariffs on imported high-resolution imaging equipment and reagents used in next generation sequencing and polymerase chain reaction assays could drive incremental cost pressures for hospitals, diagnostic laboratories, and research institutes alike. Consequently, Ambulatory Care Centers and academic research facilities may face budgetary constraints, forcing procurement teams to negotiate more aggressive supplier agreements or explore alternative vendors. On the therapeutic side, increased duties on biologic components and antifibrotic compounds imported from Europe and Asia-Pacific regions threaten to inflate drug acquisition costs for both newly diagnosed and treatment-resistant patient populations. In the absence of mitigating strategies-such as reshoring critical manufacturing steps or leveraging preferential trade agreements-these tariff-induced headwinds risk slowing adoption rates and limiting patient access to advanced care modalities.

Key Segmentation Insights

Examining the market through multiple lenses reveals nuanced opportunities and challenges across diagnostic and therapeutic domains. When considering diagnosis methods, antibody measurement and complement level assessment within blood tests continues to lead adoption, while advancements in CT scan, MRI, and ultrasound technologies foster a growing preference for noninvasive imaging. Meanwhile, histopathological examination of skin biopsy specimens is experiencing a renaissance as AI-driven pattern recognition enhances sensitivity. Shifting focus to therapeutic approaches highlights a dynamic interplay between non-pharmacological interventions-such as specialized occupational and physical therapy regimens-and pharmacological strategies where immunosuppressants, endothelin receptor antagonists, calcium channel blockers, and newly approved antifibrotic agents are driving tailored treatment plans. Age-specific considerations underscore a divergence in clinical priorities: adult cohorts benefit from long-term management protocols, geriatric patients-subdivided into young and old elderly-require careful monitoring for comorbidities, and pediatric cases demand minimally invasive diagnostics. The classification of newly diagnosed, relapsed, and treatment-resistant patients further influences the deployment of combination therapies versus monotherapy. Technological innovation also plays a central role; three-dimensional high-resolution imaging complements molecular diagnostics modalities like next generation sequencing and polymerase chain reaction, enabling precise stratification of disease phenotypes. Finally, end users spanning Ambulatory Care Centers, Diagnostic Laboratories, Hospitals, and Research Institutes-including both Academic Research and Pharmaceutical R&D-shape demand patterns alongside the clinical imperative to differentiate diffuse versus limited scleroderma and address varying severity levels, from mild presentations to major organ involvement.

Key Regional Insights

Regional dynamics in scleroderma diagnostics and therapeutics reflect disparities in healthcare infrastructure, regulatory frameworks, and research investment. In the Americas, established reimbursement pathways and robust clinical trial networks fuel rapid adoption of novel biologics and imaging platforms, while sustained partnerships between hospitals and diagnostic laboratories accelerate the translation of molecular diagnostic breakthroughs. Europe, Middle East & Africa exhibits a heterogeneous landscape: mature healthcare systems in Western Europe contrast with emerging markets in the Middle East and Africa, where limited access to specialized care drives demand for portable ultrasound and decentralized laboratory testing. Collaborative initiatives between pharmaceutical R&D centers and academic medical centers propel regional innovation, yet variability in tariff policies and import regulations often complicates procurement. In Asia-Pacific, strategic government incentives for biotech development and the proliferation of high-throughput diagnostic laboratories underpin strong growth in next generation sequencing applications. Concurrently, local manufacturing of immunosuppressants and antifibrotic agents reduces dependency on imports, mitigating some of the trade tensions experienced elsewhere. Collectively, these regional insights inform targeted go-to-market strategies and investment priorities.

Key Companies Insights

A diverse array of incumbents and emerging players is shaping the competitive environment. Major pharmaceutical companies such as AbbVie Inc., AstraZeneca plc, Bayer AG, and Novartis AG leverage expansive R&D budgets to advance novel antifibrotic and biologic therapies. Specialty firms including Antibodies Inc., Exagen Inc., and Myriad Genetics, Inc. focus on high-value molecular diagnostics platforms and proprietary biomarkers. Established diagnostics leaders like Bio-Rad Laboratories, Inc., PerkinElmer Inc., and Thermo Fisher Scientific Inc. continue to refine high-resolution imaging systems and polymerase chain reaction workflows, while Trinity Biotech plc. addresses underserved markets with cost-efficient point-of-care assays. On the biotech front, Amgen Inc., Biogen Inc., and Gilead Sciences, Inc. are exploring immunomodulatory pathways, whereas Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, and GSK advance combination therapy trials. Merck & Co., Inc., Pfizer Inc., and Sanofi Genzyme capitalize on global distribution networks to expedite market entry, and Regeneron Pharmaceuticals, Inc. collaborates with academic research hubs to accelerate translational science. Collectively, these players foster a competitive ecosystem that balances innovation with scale, driving continuous improvement in patient care.

Actionable Recommendations for Industry Leaders

To capitalize on evolving trends, industry leaders should prioritize several strategic initiatives. First, investing in integrated diagnostic platforms that combine molecular assays with imaging analytics will strengthen pipelines and reduce time to diagnosis. Second, forging alliances with payers and policy makers to navigate tariff landscapes and establish value-based reimbursement models can mitigate cost headwinds. Third, embedding artificial intelligence across histopathological and radiological workflows will enhance diagnostic precision and free clinicians to focus on therapeutic decision-making. Fourth, expanding non-pharmacological service offerings within ambulatory care settings can improve patient retention and generate ancillary revenue streams. Fifth, adopting a patient-centric segmentation strategy-tailoring interventions for newly diagnosed, relapsed, and treatment-resistant cohorts-will maximize clinical outcomes and support premium pricing. Finally, engaging in public-private collaborations within each region will accelerate localized innovation and foster sustainable growth.

Conclusion

In summary, the scleroderma diagnostics and therapeutics landscape is at a pivotal juncture where innovation, regulation, and patient needs intersect. High-resolution imaging and molecular diagnostics are redefining early detection, while next-generation pharmacotherapies and rehabilitative services offer multidimensional treatment paradigms. Tariff adjustments and regional disparities necessitate agile procurement strategies and collaborative policy engagement. Detailed segmentation analyses clarify pathways to personalized care, and competitive insights underscore the importance of strategic partnerships. By integrating technological advances with patient-centric frameworks, stakeholders can unlock new efficiencies and deliver improved clinical outcomes. This comprehensive overview equips decision-makers with the contextual intelligence needed to navigate complexities and identify high-impact opportunities.

Market Segmentation & Coverage

This research report categorizes the Scleroderma Diagnostics & Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Blood Tests
    • Antibody Measurement
    • Complement Levels
  • Imaging Techniques
    • CT Scan
    • MRI
    • Ultrasound
  • Skin Biopsy
    • Histopathological Examination
  • Non-Pharmacological Therapies
    • Occupational Therapy
    • Physical Therapy
  • Pharmacological Therapies
    • Antifibrotic Agents
    • Calcium Channel Blockers
    • Endothelin Receptor Antagonists
    • Immunosuppressants
  • Adult
  • Geriatric
    • Old Elderly
    • Young Elderly
  • Pediatric
  • Newly Diagnosed
  • Relapsed Cases
  • Treatment-Resistant
  • High-Resolution Imaging
    • 3D Imaging
  • Molecular Diagnostics
    • Next Generation Sequencing
    • Polymerase Chain Reaction
  • Ambulatory Care Centers
  • Diagnostic Laboratories
  • Hospitals
  • Research Institutes
    • Academic Research
    • Pharmaceutical R&D
  • Diffuse Scleroderma
  • Limited Scleroderma
  • Mild
  • Moderate
  • Severe
    • Life-Threatening Symptoms
    • Major Organ Involvement

This research report categorizes the Scleroderma Diagnostics & Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Scleroderma Diagnostics & Therapeutics Market to delves into recent significant developments and analyze trends in each of the following companies:

  • AbbVie Inc.
  • Amgen Inc.
  • Antibodies Inc.
  • AstraZeneca plc
  • Bayer AG
  • Bio-Rad Laboratories, Inc
  • Biogen Inc.
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Eli Lilly and Company
  • Exagen Inc.
  • F. Hoffmann-La Roche Ltd.
  • Galapagos NV
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc (GSK)
  • Merck & Co., Inc.
  • Myriad Genetics, Inc
  • Novartis AG
  • PerkinElmer Inc.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi Genzyme
  • Takeda Pharmaceutical Company Limited
  • The Bristol-Myers Squibb Company
  • Thermo Fisher Scientific Inc.
  • Trinity Biotech plc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Scleroderma Diagnostics & Therapeutics Market, by Diagnosis Method
8.1. Introduction
8.2. Blood Tests
8.2.1. Antibody Measurement
8.2.2. Complement Levels
8.3. Imaging Techniques
8.3.1. CT Scan
8.3.2. MRI
8.3.3. Ultrasound
8.4. Skin Biopsy
8.4.1. Histopathological Examination
9. Scleroderma Diagnostics & Therapeutics Market, by Therapeutic Approach
9.1. Introduction
9.2. Non-Pharmacological Therapies
9.2.1. Occupational Therapy
9.2.2. Physical Therapy
9.3. Pharmacological Therapies
9.3.1. Antifibrotic Agents
9.3.2. Calcium Channel Blockers
9.3.3. Endothelin Receptor Antagonists
9.3.4. Immunosuppressants
10. Scleroderma Diagnostics & Therapeutics Market, by Age Group
10.1. Introduction
10.2. Adult
10.3. Geriatric
10.3.1. Old Elderly
10.3.2. Young Elderly
10.4. Pediatric
11. Scleroderma Diagnostics & Therapeutics Market, by Patient Type
11.1. Introduction
11.2. Newly Diagnosed
11.3. Relapsed Cases
11.4. Treatment-Resistant
12. Scleroderma Diagnostics & Therapeutics Market, by Technology Used
12.1. Introduction
12.2. High-Resolution Imaging
12.2.1. 3D Imaging
12.3. Molecular Diagnostics
12.3.1. Next Generation Sequencing
12.3.2. Polymerase Chain Reaction
13. Scleroderma Diagnostics & Therapeutics Market, by End Users
13.1. Introduction
13.2. Ambulatory Care Centers
13.3. Diagnostic Laboratories
13.4. Hospitals
13.5. Research Institutes
13.5.1. Academic Research
13.5.2. Pharmaceutical R&D
14. Scleroderma Diagnostics & Therapeutics Market, by Onset Type
14.1. Introduction
14.2. Diffuse Scleroderma
14.3. Limited Scleroderma
15. Scleroderma Diagnostics & Therapeutics Market, by Severity Level
15.1. Introduction
15.2. Mild
15.3. Moderate
15.4. Severe
15.4.1. Life-Threatening Symptoms
15.4.2. Major Organ Involvement
16. Americas Scleroderma Diagnostics & Therapeutics Market
16.1. Introduction
16.2. Argentina
16.3. Brazil
16.4. Canada
16.5. Mexico
16.6. United States
17. Asia-Pacific Scleroderma Diagnostics & Therapeutics Market
17.1. Introduction
17.2. Australia
17.3. China
17.4. India
17.5. Indonesia
17.6. Japan
17.7. Malaysia
17.8. Philippines
17.9. Singapore
17.10. South Korea
17.11. Taiwan
17.12. Thailand
17.13. Vietnam
18. Europe, Middle East & Africa Scleroderma Diagnostics & Therapeutics Market
18.1. Introduction
18.2. Denmark
18.3. Egypt
18.4. Finland
18.5. France
18.6. Germany
18.7. Israel
18.8. Italy
18.9. Netherlands
18.10. Nigeria
18.11. Norway
18.12. Poland
18.13. Qatar
18.14. Russia
18.15. Saudi Arabia
18.16. South Africa
18.17. Spain
18.18. Sweden
18.19. Switzerland
18.20. Turkey
18.21. United Arab Emirates
18.22. United Kingdom
19. Competitive Landscape
19.1. Market Share Analysis, 2024
19.2. FPNV Positioning Matrix, 2024
19.3. Competitive Analysis
19.3.1. AbbVie Inc.
19.3.2. Amgen Inc.
19.3.3. Antibodies Inc.
19.3.4. AstraZeneca plc
19.3.5. Bayer AG
19.3.6. Bio-Rad Laboratories, Inc
19.3.7. Biogen Inc.
19.3.8. Boehringer Ingelheim Pharmaceuticals, Inc.
19.3.9. Eli Lilly and Company
19.3.10. Exagen Inc.
19.3.11. F. Hoffmann-La Roche Ltd.
19.3.12. Galapagos NV
19.3.13. Gilead Sciences, Inc.
19.3.14. GlaxoSmithKline plc (GSK)
19.3.15. Merck & Co., Inc.
19.3.16. Myriad Genetics, Inc
19.3.17. Novartis AG
19.3.18. PerkinElmer Inc.
19.3.19. Pfizer Inc.
19.3.20. Regeneron Pharmaceuticals, Inc.
19.3.21. Sanofi Genzyme
19.3.22. Takeda Pharmaceutical Company Limited
19.3.23. The Bristol-Myers Squibb Company
19.3.24. Thermo Fisher Scientific Inc.
19.3.25. Trinity Biotech plc.
20. ResearchAI
21. ResearchStatistics
22. ResearchContacts
23. ResearchArticles
24. Appendix
List of Figures
FIGURE 1. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET MULTI-CURRENCY
FIGURE 2. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET MULTI-LANGUAGE
FIGURE 3. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS METHOD, 2024 VS 2030 (%)
FIGURE 8. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS METHOD, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2024 VS 2030 (%)
FIGURE 10. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 12. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TECHNOLOGY USED, 2024 VS 2030 (%)
FIGURE 16. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TECHNOLOGY USED, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USERS, 2024 VS 2030 (%)
FIGURE 18. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USERS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ONSET TYPE, 2024 VS 2030 (%)
FIGURE 20. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ONSET TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SEVERITY LEVEL, 2024 VS 2030 (%)
FIGURE 22. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SEVERITY LEVEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 26. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. EUROPE, MIDDLE EAST & AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 30. EUROPE, MIDDLE EAST & AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 32. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ANTIBODY MEASUREMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COMPLEMENT LEVELS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CT SCAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MRI, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SKIN BIOPSY, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HISTOPATHOLOGICAL EXAMINATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SKIN BIOPSY, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY OCCUPATIONAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY OLD ELDERLY, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY YOUNG ELDERLY, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEWLY DIAGNOSED, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RELAPSED CASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT-RESISTANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TECHNOLOGY USED, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HIGH-RESOLUTION IMAGING, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY 3D IMAGING, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HIGH-RESOLUTION IMAGING, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ACADEMIC RESEARCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL R&D, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ONSET TYPE, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIFFUSE SCLERODERMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY LIMITED SCLERODERMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MILD, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MODERATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SEVERE, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY LIFE-THREATENING SYMPTOMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MAJOR ORGAN INVOLVEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SEVERE, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SKIN BIOPSY, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TECHNOLOGY USED, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HIGH-RESOLUTION IMAGING, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ONSET TYPE, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SEVERE, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SKIN BIOPSY, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TECHNOLOGY USED, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HIGH-RESOLUTION IMAGING, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ONSET TYPE, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SEVERE, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SKIN BIOPSY, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TECHNOLOGY USED, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HIGH-RESOLUTION IMAGING, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ONSET TYPE, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SEVERE, 2018-2030 (USD MILLION)
TABLE 122. CANADA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 123. CANADA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 124. CANADA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 125. CANADA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SKIN BIOPSY, 2018-2030 (USD MILLION)
TABLE 126. CANADA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 127. CANADA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 128. CANADA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 129. CANADA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 130. CANADA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 131. CANADA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 132. CANADA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TECHNOLOGY USED, 2018-2030 (USD MILLION)
TABLE 133. CANADA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HIGH-RESOLUTION IMAGING, 2018-2030 (USD MILLION)
TABLE 134. CANADA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 135. CANADA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 136. CANADA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 137. CANADA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ONSET TYPE, 2018-2030 (USD MILLION)
TABLE 138. CANADA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 139. CANADA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SEVERE, 2018-2030 (USD MILLION)
TABLE 140. MEXICO SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 141. MEXICO SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 142. MEXICO SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 143. MEXICO SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SKIN BIOPSY, 2018-2030 (USD MILLION)
TABLE 144. MEXICO SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 145. MEXICO SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 146. MEXICO SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 147. MEXICO SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 148. MEXICO SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 149. MEXICO SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 150. MEXICO SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TECHNOLOGY USED, 2018-2030 (USD MILLION)
TABLE 151. MEXICO SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HIGH-RESOLUTION IMAGING, 2018-2030 (USD MILLION)
TABLE 152. MEXICO SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 153. MEXICO SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 154. MEXICO SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 155. MEXICO SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ONSET TYPE, 2018-2030 (USD MILLION)
TABLE 156. MEXICO SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 157. MEXICO SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SEVERE, 2018-2030 (USD MILLION)
TABLE 158. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 159. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 160. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 161. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SKIN BIOPSY, 2018-2030 (USD MILLION)
TABLE 162. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 163. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 164. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 165. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 166. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 167. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 168. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TECHNOLOGY USED, 2018-2030 (USD MILLION)
TABLE 169. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HIGH-RESOLUTION IMAGING, 2018-2030 (USD MILLION)
TABLE 170. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 171. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 172. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 173. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ONSET TYPE, 2018-2030 (USD MILLION)
TABLE 174. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 175. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SEVERE, 2018-2030 (USD MILLION)
TABLE 176. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 177. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 178. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 179. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 180. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SKIN BIOPSY, 2018-2030 (USD MILLION)
TABLE 181. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 182. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 183. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 184. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 185. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 186. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 187. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TECHNOLOGY USED, 2018-2030 (USD MILLION)
TABLE 188. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HIGH-RESOLUTION IMAGING, 2018-2030 (USD MILLION)
TABLE 189. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 190. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 191. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 192. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ONSET TYPE, 2018-2030 (USD MILLION)
TABLE 193. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 194. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SEVERE, 2018-2030 (USD MILLION)
TABLE 195. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 196. AUSTRALIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 197. AUSTRALIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 198. AUSTRALIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 199. AUSTRALIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SKIN BIOPSY, 2018-2030 (USD MILLION)
TABLE 200. AUSTRALIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 201. AUSTRALIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 202. AUSTRALIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 203. AUSTRALIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 204. AUSTRALIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 205. AUSTRALIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 206. AUSTRALIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TECHNOLOGY USED, 2018-2030 (USD MILLION)
TABLE 207. AUSTRALIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HIGH-RESOLUTION IMAGING, 2018-2030 (USD MILLION)
TABLE 208. AUSTRALIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 209. AUSTRALIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 210. AUSTRALIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 211. AUSTRALIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ONSET TYPE, 2018-2030 (USD MILLION)
TABLE 212. AUSTRALIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 213. AUSTRALIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SEVERE, 2018-2030 (USD MILLION)
TABLE 214. CHINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 215. CHINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 216. CHINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 217. CHINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SKIN BIOPSY, 2018-2030 (USD MILLION)
TABLE 218. CHINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 219. CHINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 220. CHINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 221. CHINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 222. CHINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 223. CHINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 224. CHINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TECHNOLOGY USED, 2018-2030 (USD MILLION)
TABLE 225. CHINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HIGH-RESOLUTION IMAGING, 2018-2030 (USD MILLION)
TABLE 226. CHINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 227. CHINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 228. CHINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 229. CHINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ONSET TYPE, 2018-2030 (USD MILLION)
TABLE 230. CHINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 231. CHINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SEVERE, 2018-2030 (USD MILLION)
TABLE 232. INDIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 233. INDIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 234. INDIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 235. INDIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SKIN BIOPSY, 2018-2030 (USD MILLION)
TABLE 236. INDIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 237. INDIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 238. INDIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 239. INDIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 240. INDIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 241. INDIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 242. INDIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TECHNOLOGY USED, 2018-2030 (USD MILLION)
TABLE 243. INDIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HIGH-RESOLUTION IMAGING, 2018-2030 (USD MILLION)
TABLE 244. INDIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 245. INDIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 246. INDIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 247. INDIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ONSET TYPE, 2018-2030 (USD MILLION)
TABLE 248. INDIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 249. INDIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SEVERE, 2018-2030 (USD MILLION)
TABLE 250. INDONESIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 251. INDONESIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 252. INDONESIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 253. INDONESIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SKIN BIOPSY, 2018-2030 (USD MILLION)
TABLE 254. INDONESIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 255. INDONESIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 256. INDONESIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 257. INDONESIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 258. INDONESIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 259. INDONESIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 260. INDONESIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TECHNOLOGY USED, 2018-2030 (USD MILLION)
TABLE 261. INDONESIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HIGH-RESOLUTION IMAGING, 2018-2030 (USD MILLION)
TABLE 262. INDONESIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 263. INDONESIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 264. INDONESIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 265. INDONESIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ONSET TYPE, 2018-2030 (USD MILLION)
TABLE 266. INDONESIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 267. INDONESIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SEVERE, 2018-2030 (USD MILLION)
TABLE 268. JAPAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 269. JAPAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 270. JAPAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 271. JAPAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SKIN BIOPSY, 2018-2030 (USD MILLION)
TABLE 272. JAPAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 273. JAPAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 274. JAPAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 275. JAPAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 276. JAPAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 277. JAPAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 278. JAPAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TECHNOLOGY USED, 2018-2030 (USD MILLION)
TABLE 279. JAPAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HIGH-RESOLUTION IMAGING, 2018-2030 (USD MILLION)
TABLE 280. JAPAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 281. JAPAN SCLERODERMA DIAGNOSTICS & THERAPEU

Companies Mentioned

  • AbbVie Inc.
  • Amgen Inc.
  • Antibodies Inc.
  • AstraZeneca plc
  • Bayer AG
  • Bio-Rad Laboratories, Inc
  • Biogen Inc.
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Eli Lilly and Company
  • Exagen Inc.
  • F. Hoffmann-La Roche Ltd.
  • Galapagos NV
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc (GSK)
  • Merck & Co., Inc.
  • Myriad Genetics, Inc
  • Novartis AG
  • PerkinElmer Inc.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi Genzyme
  • Takeda Pharmaceutical Company Limited
  • The Bristol-Myers Squibb Company
  • Thermo Fisher Scientific Inc.
  • Trinity Biotech plc.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Scleroderma Diagnostics and Therapeutics - Global Strategic Business Report - Product Image

Scleroderma Diagnostics and Therapeutics - Global Strategic Business Report

  • Report
  • 194 Pages
  • Global
From
Scleroderma Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Immunosuppressors, ERA, CCBs, PA), By Indication (Systemic, Localized), By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Scleroderma Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Immunosuppressors, ERA, CCBs, PA), By Indication (Systemic, Localized), By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 70 Pages
  • Global
From
Systemic Scleroderma - Pipeline Insight, 2025 - Product Image

Systemic Scleroderma - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Localized Scleroderma - Pipeline Insight, 2025 - Product Image

Localized Scleroderma - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Scleroderma Therapeutics Market 2024-2028 - Product Image

Scleroderma Therapeutics Market 2024-2028

  • Report
  • 130 Pages
  • Global
From

About the Scleroderma Drug Market

Scleroderma is a chronic autoimmune disorder that affects the skin and other organs. Dermatological drugs are used to treat the symptoms of scleroderma, including skin thickening, joint pain, and fatigue. These drugs can be divided into two categories: immunosuppressants and biologics. Immunosuppressants are used to reduce inflammation and suppress the immune system, while biologics are used to target specific proteins that are involved in the disease process. The scleroderma drug market is highly competitive, with a number of companies offering treatments for the condition. Some of the major players in the market include Pfizer, Novartis, AbbVie, and Sanofi. These companies offer a range of treatments, including immunosuppressants, biologics, and other drugs. Additionally, there are a number of smaller companies that specialize in scleroderma treatments, such as Galapagos, FibroGen, and Fibrocell. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.